These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17340468)

  • 1. Single-chain antibodies as new antithrombotic drugs.
    Hagemeyer CE; Schwarz M; Peter K
    Semin Thromb Hemost; 2007 Mar; 33(2):185-95. PubMed ID: 17340468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Helping antibodies. Targeted antithrombotic and fibrinolytic therapy].
    Schwarz M; Hagemeyer CE; Peter K; Bode C
    Hamostaseologie; 2007 Dec; 27(5):360-2. PubMed ID: 18060247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-chain antibodies as diagnostic tools and therapeutic agents.
    Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
    Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
    Weisser NE; Hall JC
    Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycosylation of recombinant antibody therapeutics.
    Jefferis R
    Biotechnol Prog; 2005; 21(1):11-6. PubMed ID: 15903235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody engineering: facing new challenges in cancer therapy.
    Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
    Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered single chain antibody fragments for radioimmunotherapy.
    Huhalov A; Chester KA
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of antibody fragments in Arabidopsis seeds.
    Van Droogenbroeck B; De Wilde K; Depicker A
    Methods Mol Biol; 2009; 483():89-101. PubMed ID: 19183895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antibody therapeutics by design.
    Carter PJ
    Nat Rev Immunol; 2006 May; 6(5):343-57. PubMed ID: 16622479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies in therapeutic applications.
    Roovers RC; van Dongen GA; van Bergen en Henegouwen PM
    Curr Opin Mol Ther; 2007 Aug; 9(4):327-35. PubMed ID: 17694445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered antibody fragments and the rise of single domains.
    Holliger P; Hudson PJ
    Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative antibody formats.
    Kontermann RE
    Curr Opin Mol Ther; 2010 Apr; 12(2):176-83. PubMed ID: 20373261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
    Rothe C; Urlinger S; Löhning C; Prassler J; Stark Y; Jäger U; Hubner B; Bardroff M; Pradel I; Boss M; Bittlingmaier R; Bataa T; Frisch C; Brocks B; Honegger A; Urban M
    J Mol Biol; 2008 Feb; 376(4):1182-200. PubMed ID: 18191144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of nanobodies for therapeutic applications.
    Van Bockstaele F; Holz JB; Revets H
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
    Ranft K; Thepen T; Fischer R; Barth S; Stöcker M
    Cancer Lett; 2009 Sep; 282(2):187-94. PubMed ID: 19345477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.